Background: Hereditary angioedema (HAE) related to C1-inhibitor deficiency is a rare autosomal dominant disorder. Vascular cell adhesion molecules (VCAM) are known as endothelial activation markers. Endocan (also called ESM-1) is proposed as an endothelial dysfunction indicator. We aimed to investigate endothelial activation in attack-free periods in HAE patients by measuring their levels of endocan and VCAM-1. Methods: Twenty-six HAE patients (22 female, mean age 40 ± 13 years) and 38 healthy control patients (13 female, mean age 36.9 ± 12 years) were included in the study. Peripheral blood samples were collected from HAE patients during symptom-free periods and control subjects. Endocan and VCAM-1 levels were measured using the enzyme-linked immunosorbent assay method. Results: The median serum levels of endocan (647 ± 101 ng/mL) and VCAM-1 (500 ± 79 ng/mL) in the HAE patients were significantly higher than in the control patients (391 ± 41 and 325 ± 4; p < 0.001 for both). Conclusion: The increased endocan and VCAM-1 levels may reflect an endothelial activation even in attack-free periods in HAE patients.

Keywords:
C1-inhibitor deficiency, Endocan, Hereditary angioedema, Vascular cell adhesion molecules
1.
Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, et al: Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114:S51-S131.
2.
Ghebrehiwet B, Kaplan AP, Joseph K, Peerschke EI: The complement and contact activation systems: partnership in pathogenesis beyond angioedema. Immunol Rev 2016;274:281-289.
3.
Nielsen EW, Johansen HT, Høgåsen K, Wuillemin W, Hack CE, Mollnes TE: Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 1996;44:185-192.
4.
Bossi F, Fischetti F, Regoli D, Frossi B, Gobeil F Jr, Ghebrehiwet B, Peerschke EI, Cicardi M, Tedesco F: Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009;124:1303-1310.
5.
Zuraw BL, Christiansen SC: HAE pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol 2016;51:216-229.
6.
Czúcz J, Schaffer GD, Csuka D, Prohászka Z, Farkas HL, Cervenak L: Endothelial cell function in patients with hereditary angioedema: elevated soluble E-selectin level during inter-attack periods. J Clin Immunol 2012;32:61-69.
7.
Kajdacsi E, Jani PK, Csuka D, Varga LA, Prohaszka Z, Farkas H, Cervenak L: Endothelial cell activation during edematous attacks of hereditary angioedema types I and II. J Allergy Clin Immunol 2014;133:1686-1691.
8.
Demirtürk M, Gelincik A, Cınar S, Kilercik M, Onay-Ucar E, Çolakoğlu B, et al: Increased eNOS levels in hereditary angioedema. Int Immunopharmacol 2014;20:264-268.
9.
Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al: Endocan orendothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
10.
Cox LA, van Eijk LT, Ramakers BP, Dorresteijn MJ, Gerretsen J, Kox M, et al: Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock 2015;43:322-326.
11.
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A: Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015;243:339-343.
12.
Filep JG: Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis? Crit Care Med 2006;34:574-575.
13.
Balta S, Mikhailidis DP, Demirkol S, Celik T, Ozturk C, Iyisoy A: Endocan and atherosclerosis. Angiology 2015;66:490.
14.
Lee W, Ku SK, Kim SW, Bae JS: Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014;229:620-630.
15.
Liao JK: Linking endothelial dysfunction with endothelial cell activation. Clin Invest 2013;123:540-541.
16.
Loffredo S, Bova M, Suffritti C, Borriello F, Zanichelli A, Petraroli A, et al: Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema. Allergy 2016;71:989-996.
17.
Pauly D, Hamed S, Behnes M, Lepiorz D, Lang S, Akin I, et al: Endothelial cell-specific molecule-1/endocan: diagnostic and prognostic value in patients suffering from severe sepsis and septic shock. J Crit Care 2016;31:68-75.
18.
Delehedde M, Devenyns L, Maurage CA, Vives RR: Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013;2013:705027.
19.
Lassalle P, Molet S, Janin A, van der Heyden J, Tavernier J, Fiers W, et al: ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-20464.
20.
Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al: Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417-425.
21.
Demirtürk M, Polat N, Güz G, Gürdal A, Altun I, Gelincik A, et al: There is an increased risk of atherosclerosis in hereditary angioedema. Int Immunopharmacol 2012;12:212-216.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.